The Efficacy And Safety Analysis Of Xintai Combined With Chemotherapy For Newly Diagnosed Multiple Myeloma And Literature Review

Objective: To analyze and evaluate the clinical effect and safety of domestic bortezomib combined with chemotherapy in the treatment of newly diagnosed multiple myeloma(NDMM).Methods: From February 2018 to December 2019,the clinical information of 26 newly diagnosed active multiple myeloma(MM)patients treated with Xintai combined chemotherapy in the Department of Hematology,Third Hospital of Hebei Medical University was collected,and the efficacy and safety of Xintai were retrospectively analyzed and evaluated.The patients received 4~8 cycles of chemotherapy,and the efficacy and safety were evaluated at the 4th,6th and 8th cycles respectively.Results: During the follow-up to January 31,2020,among the 26 NDMM patients treated with Xintai-based combination chemotherapy,all patients could be evaluated at 4 cycles,including 2 patients were complete remission(CR),10 patients had very good partial remission(VGPR),10 cases were partial remission(PR),2 cases were mild remission(MR),2 case were stable disease(SD),the response rate reaching above VGPR level was 46.15%,and the overall response rate was 84.62%.16 patients could be evaluated at 6 cycles,including 3 cases of CR,7 cases of VGPR,4 cases of PR,2 cases of progress disease(PD),the response rate reaching above VGPR level was 62.50%,ORR 87.50%;7 patients could be evaluated at 8 cycles,all of which reached above VGPR(3 CR and 4 VGPR),and ORR was 100%.The main adverse reactions of Xintai include gastrointestinal reaction,infection,peripheral neuropathy,toxicity of blood system,etc.Except for the toxicity of blood system,the other adverse reactionswere all grade 1~2,which could be improved after symptomatic treatment and dose adjustment.Conclusion: Xintai is effective and safe in the treatment of NDMM;The ORR,CR rate and VGPR rate gradually increased as the number of courses of Xin-Tai combined chemotherapy increased.